Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -23.00
- Piotroski Score 3.00
- Grade Neutral
- Symbol (ACOR)
- Company Acorda Therapeutics, Inc.
- Price $0.66
- Changes Percentage (-24.02%)
- Change -$0.21
- Day Low $0.61
- Day High $0.85
- Year High $24.20
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 05/01/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$203.57
- Trailing P/E Ratio -0.0032470403301076
- Forward P/E Ratio -0.0032470403301076
- P/E Growth -0.0032470403301076
- Net Income $-252,854,000
Income Statement
Quarterly
Annual
Latest News of ACOR
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
At Botanic Garden, a Miniature New York Made of Bark and Acorns
The New York Botanical Garden's model train show features famous city buildings made of plant materials. The State Department of Labor is investigating Shen Yun Performing Arts for labor practices. Th...
By The New York Times | 17 hours ago -
Country Diary: A quiet autumn for acorns so far - but this oak tree is being productive | Mary Montague
In Lagan Valley, County Antrim, the author observes the changing seasons, from the fading light of autumn to the resilient fungi thriving in the woods....
By The Guardian | 1 week ago -
Idacorp Inc (IDA) Q3 2024 Earnings Call Highlights: Strong Earnings Growth and Strategic ...
Brian Buckham, CFO, expects consistent earnings around support levels with a gradual reduction in tax credit reliance. Lisa Grow, CEO, highlights the importance of balancing dispatchable and intermitt...
By Yahoo! Finance | 2 weeks ago
